The Tyrosine Protein Phosphatase Non Receptor Type Substrate 1 pipeline drugs market research report outlays comprehensive information on the Tyrosine Protein Phosphatase Non Receptor Type Substrate 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Tyrosine Protein Phosphatase Non Receptor Type Substrate 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Cardiovascular, Immunology, and Hematological Disorders which include the indications Solid Tumor, Unspecified Cancer, Cardiovascular Disease, Pulmonary Arterial Hypertension, Inflammation, Autoimmune Disorders, and Hemophagocytic Lymphohistiocytosis. It also reviews key players involved in Tyrosine Protein Phosphatase Non Receptor Type Substrate 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Tyrosine Protein Phosphatase Non Receptor Type Substrate 1 pipeline targets constitutes close to 31 molecules. Out of which, approximately 30 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 8, 6, 10, and 6 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Tyrosine Protein Phosphatase Non Receptor Type Substrate 1 overview
Tyrosine-protein phosphatase non-receptor type 1 (PTPN1) is an enzyme that regulates the endoplasmic reticulum unfolded protein response. It also acts as a candidate regulator of neuroblastoma cell growth and a potential neuroblastoma prognostic biomarker. PTP1B is a major negative regulator of numerous signaling cascades of metabolic and/or oncogenic relevance such as the insulin or epidermal growth factor (EGF) pathways.
For a complete picture of Tyrosine Protein Phosphatase Non Receptor Type Substrate 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
